Supply constraints push EpiPen rival maker Amneal to restructure, shares fall
Amneal Pharmaceuticals, which sells a generic epinephrine auto-injector similar to Mylan’s flagship Epipen, has initiated a sweeping restructuring of its business driven primarily by the uncertainty surrounding the supply of the emergency shot.
The Bridgewater, New Jersey-based company — which develops and sells a raft of generic, brand and biosimilar products — last year in May swallowed Impax Laboratories gaining access to its life-saving allergy shot Adrenaclick. Days later, the FDA said the product, along with Mylan’s $MYL EpiPen, were experiencing shortages. As of June 2019, Mylan and Amneal continue to face supply constraints, according to the health regulator.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.